Recent Updates
Recently added Catalysts
MDAI Positive Sentiment Score: 70/100

Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call

Key Takeaway: Spectral AI, Inc. will report its second quarter financial results on August 11, 2026, followed by a conference call at 5:00 PM ET. The company focuses on AI-driven medical diagnostics for wound care, particularly for burns, and aims to improve treatment decisions. The DeepView System is designed to provide immediate assessments of wound healing potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • Spectral AI is focused on improving wound care diagnostics.
  • The company has been recognized by TIME as a top HealthTech company.
  • The DeepView System aims to enhance treatment accuracy and patient outcomes.

CONCERNS & RISKS

  • Forward-looking statements involve risks and uncertainties.
  • Actual results may differ from projections due to various factors.

Full Press Release Details

DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.
Investors interested in participating in the live call can dial into the conference call as follows:
• 833-890-6620 – U.S.
• 412-564-3789 – International
In addition, a simultaneous webcast of the financial results call may be accessed online from the Events section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events.
About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to exceed the current standard of care, the DeepView System provides fast and accurate treatment insights to improve patient outcomes and reduce healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Investors: The Equity Group
Devin Sullivan Managing Director Devin.Sullivan@theequitygroup.com Conor Rodriguez Associate Conor.Rodriguez@theequitygroup.com

Frequently Asked Questions

When will Spectral AI report its Q2 financial results?

Spectral AI will report its Q2 financial results on August 11, 2026.

What is the purpose of the conference call?

The conference call will discuss the financial results for the second quarter.

How can investors join the conference call?

Investors can join by calling 833-890-6620 for U.S. or 412-564-3789 internationally.

What is the DeepView System?

The DeepView System is a predictive diagnostic device for assessing wound healing potential.

What recognition has Spectral AI received?

Spectral AI was named to TIME's list of World's Top HealthTech companies in 2025.

Last updated: Jul 29, 2026